Crixivan

RSS

indinavir

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Crixivan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Crixivan.

This EPAR was last updated on 04/12/2018

Authorisation details

Product details
Name
Crixivan
Agency product number
EMEA/H/C/000128
Active substance
indinavir sulfate ethanolate
International non-proprietary name (INN) or common name
indinavir
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AE02
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Revision
39
Date of issue of marketing authorisation valid throughout the European Union
04/10/1996
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

03/08/2018 Crixivan - EMEA/H/C/000128 - T/0104

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.

Assessment history

How useful was this page?

Add your rating